医疗团体敦促HHS澄清药品销售和反法律的联邦指导. Healthcare groups urge HHS to clarify federal guidance on drug sales and anti-kickback laws.

2026年4月4日,主要医疗保健团体和制药公司敦促美国卫生与人类服务部澄清联邦对直接向消费者销售药品计划及反法律的指导. Major healthcare groups and pharmaceutical companies urged the U.S. Department of Health and Human Services on April 4, 2026, to clarify federal guidance on direct-to-consumer drug sales programs and anti-kickback laws. 包括PhRMA,Pfizer和美国药剂师协会在内的行业利益相关者提交了公开意见,要求制定更明确的标准以平衡监管与患者获得关键治疗方法,特别是慢性疾病. The industry stakeholders, including PhRMA, Pfizer, and the American Pharmacists Association, submitted public comments requesting clearer standards to balance regulatory oversight with patient access to critical treatments, particularly for chronic conditions.